Amneal Pharmaceuticals, Inc.
$13.26
▼
-1.81%
2026-04-21 05:17:00
www.amneal.com
NMS: AMRX
Explore Amneal Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.23 B
Current Price
$13.26
52W High / Low
$15.42 / $7.01
Stock P/E
58.7
Book Value
$-0.23
Dividend Yield
—
ROCE
14.23%
ROE
-80.04%
Face Value
—
EPS
$0.22
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
8,700
Beta
1.32
Debt / Equity
45,095.52
Current Ratio
2.17
Quick Ratio
1.48
Forward P/E
10.66
Price / Sales
1.33
Enterprise Value
$6.42 B
EV / EBITDA
9.97
EV / Revenue
2.13
Rating
None
Target Price
$16.8
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Amylyx Pharmaceuticals, Inc. | $17.57 | — | $2.03 B | — | -49.46% | -61.59% | $18.61 / $3.79 | $2.78 |
| 2. | Cumberland Pharmaceuticals Inc. | $3.15 | — | $47.57 M | — | -6.97% | -12.17% | $6.27 / $1.85 | $1.66 |
| 3. | InMed Pharmaceuticals Inc. | $0.72 | — | $2.4 M | — | -57.63% | -97.2% | $7.98 / $0.57 | $3.42 |
| 4. | Akebia Therapeutics, Inc. | $1.43 | — | $381.73 M | — | 11% | 64.49% | $4.08 / $1.14 | $0.12 |
| 5. | Zoetis Inc. | $118.25 | 19.63 | $49.71 B | 1.64% | 27.18% | 65.99% | $172.23 / $113.29 | $7.84 |
| 6. | Organogenesis Holdings Inc. | $2.52 | 8.75 | $324.17 M | — | 11.21% | 9.04% | $7.08 / $2.21 | $2.36 |
| 7. | Apimeds Pharmaceuticals US, Inc. | $1.88 | — | $23.64 M | — | 126.09% | 209.61% | $40.31 / $1.61 | $0.65 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 814.32 M | 784.51 M | 724.51 M | 695.42 M | 730.52 M | — |
| Operating Profit | 114.5 M | 70.49 M | 112.01 M | 100.92 M | 78.07 M | — |
| Net Profit | 35.08 M | 2.37 M | 22.42 M | 12.2 M | -31.08 M | — |
| EPS in Rs | 0.11 | 0.01 | 0.07 | 0.04 | -0.1 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.02 B | 2.79 B | 2.39 B | 2.21 B |
| Operating Profit | 397.91 M | 348.37 M | 238.75 M | 188.92 M |
| Net Profit | 72.06 M | -116.89 M | -83.99 M | -129.99 M |
| EPS in Rs | 0.23 | -0.37 | -0.26 | -0.41 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 3.68 B | 3.5 B | 3.47 B | 3.8 B |
| Total Liabilities | 3.75 B | 3.61 B | 3.45 B | 3.62 B |
| Equity | -70.79 M | -109.27 M | 19.78 M | 298.42 M |
| Current Assets | 1.91 B | 1.59 B | 1.38 B | 1.41 B |
| Current Liabilities | 881.63 M | 1.13 B | 846.6 M | 752.8 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 339.99 M | 295.1 M | 345.58 M | 65.1 M |
| Investing CF | -112.26 M | -63 M | -69.19 M | -174.31 M |
| Financing CF | -31.53 M | -211.79 M | -212.57 M | -106.62 M |
| Free CF | 225.63 M | 220.11 M | 276.39 M | -25.5 M |
| Capex | -114.36 M | -74.99 M | -69.19 M | -90.59 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 16.73% | 8.2% | — | — |
| Earnings Growth % | -39.16% | 35.38% | — | — |
| Profit Margin % | -4.18% | -3.51% | -5.88% | — |
| Operating Margin % | 12.47% | 9.97% | 8.54% | — |
| Gross Margin % | 36.52% | 34.28% | 35.47% | — |
| EBITDA Margin % | 15.74% | 16.7% | 6.8% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.